Multisystem immune-related adverse events due to toripalimab: Two cases-based review

Immune checkpoint inhibitors (ICIs) have significantly improved the survival of patients with advanced tumors. However, immune-related adverse events (irAEs) caused by ICIs, especially high-grade irAEs, are of growing concern. High-grade multisystem irAEs due to toripalimab, a programmed cell death-...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yanran, Chen, Yulan, Xie, Jingyi, Liu, Dongzhou, Hong, Xiaoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732722/
https://www.ncbi.nlm.nih.gov/pubmed/36505392
http://dx.doi.org/10.3389/fcvm.2022.1036603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732722/
https://www.ncbi.nlm.nih.gov/pubmed/36505392
http://dx.doi.org/10.3389/fcvm.2022.1036603

Ejemplares similares